Direct answer: Medical cannabis suppositories deliver cannabinoids through the rectal or vaginal lining instead of the gut. The pharmacokinetic research is small and specific: THC itself is poorly absorbed rectally, while a chemically modified prodrug, THC-hemisuccinate, produced higher blood levels than oral THC in studies involving a few dozen people. No such product is sold commercially, and in South Africa any THC suppository is a Schedule 6 prescription medicine.
Last updated:
Key takeaways
- Plain THC barely crosses the rectal lining. Monkey studies by ElSohly and colleagues in 1991 found no THC bioavailability from suppositories of THC itself.
- The encouraging numbers come from a prodrug, THC-hemisuccinate: about 2.4 times the THC exposure of an oral capsule in 12 healthy men (2018).
- The human evidence is tiny: three women in 1993, two patients in 1996, 42 healthy men in 2018 and one 12-person manufacturer study in 2025.
- For the vaginal route there is interest but no published human pharmacokinetic study that we could find.
- In South Africa a THC suppository is a Schedule 6 medicine: registered doctor, section 21 where unregistered, registered pharmacy.
- No dosing or insertion instructions here. General information for adults 18 and over, not medical advice.
If you are asking whether a non-oral cannabis medicine could suit you, the honest starting point is a doctor who can weigh the evidence against your history. Create your Professor Green account to begin that route. Registration is a first step only and does not guarantee eligibility, a prescription or supply.
What are medical cannabis suppositories?
They are solid doses made with a fatty or water-soluble base that melts or dissolves at body temperature, carrying THC, CBD or a derivative across the lining of the rectum or vagina. The idea is to bypass the stomach and part of the first pass through the liver, which limits how much swallowed THC reaches the circulation.
That rationale holds for many ordinary medicines. The question for cannabis is narrower: does THC actually cross that lining in useful amounts? In the published studies the answer depends on the chemical form of THC far more than on the suppository itself.
It also matters what you compare against. Swallowed THC is the usual benchmark, and a weak one: Marilyn Huestis’s 2007 review reported oral THC bioavailability of 10 to 20 percent, with considerable variability. Our guide to how much of a cannabis dose actually reaches you sets out the route-by-route figures.
Is THC absorbed through the rectum?
Not well in its ordinary form. Animal studies by ElSohly and colleagues in 1991 found no THC bioavailability from various suppository formulations of THC itself, and the same group wrote in 2018 that THC is not absorbed rectally. Absorption only became measurable when THC was converted into a more water-friendly prodrug.
The prodrug is THC-hemisuccinate, an ester that crosses the rectal lining and is then broken down in the blood to release ordinary THC. In rhesus monkeys, ElSohly and colleagues (J Pharm Sci, 1991) calculated THC bioavailability of 13.5 percent from a hemisuccinate suppository in a Witepsol H15 base, and THC stayed in the body longer than after an intravenous dose, with a mean residence time of 5.8 hours against about 3 hours.
A companion 1991 paper found that, in a fatty base, only the hemisuccinate among several esters produced detectable THC in monkeys, and in conscious dogs it gave 67 percent bioavailability.
That is uncomfortable for anyone selling a home-style cannabis suppository. The formulation that worked was a specific prodrug in a specific base; cannabis extract mixed into cocoa butter is not that product.
What did the human studies of THC suppositories find?
They found higher and steadier THC exposure than oral capsules, but in very few people. Across three studies of the hemisuccinate prodrug, the total is three women, two patients with spasticity and 42 healthy male volunteers, and only one of those studies was designed to compare the routes formally.
The first was a 1993 report by Mattes and colleagues. Three adult women, two of whom had shown low blood levels after an oral THC capsule, received a hemisuccinate suppository, and the area under the plasma THC curve was more than 30-fold higher than after oral dosing. With two of three participants selected for poor oral absorption, that figure describes those individuals, not a typical patient.
The second, a 1996 pilot by Brenneisen and colleagues in two patients with spasticity, estimated oral bioavailability at 45 to 53 percent of the rectal route, which Huestis summarised in 2007 as rectal bioavailability approximately twice that of oral. Improvement in those two patients is an observation, not evidence of effectiveness.
The most rigorous is the 2018 study by ElSohly, Gul and Walker. In 30 men, ascending suppository doses were tested against placebo and exposure rose broadly with dose. In a second cohort, 12 men received an oral dronabinol capsule and an equivalent hemisuccinate suppository in crossover: THC exposure was 2.44 times higher after the suppository (90 percent confidence interval 1.78 to 3.35), while peak levels were lower and later. No safety issues were reported.
A 2025 single-dose trial by Tarlovski and colleagues, run by the manufacturer in 12 healthy volunteers, found its novel suppository gave substantial exposure but somewhat lower bioavailability than oromucosal comparators. A modern cannabis suppository is not automatically better absorbed than an oil held in the mouth.
| Route and form | What reaches the bloodstream | Human evidence behind it | Practical status |
|---|---|---|---|
| Oral THC capsule (dronabinol) | Huestis 2007 reports oral THC bioavailability of 10 to 20 percent; absorption is slow and variable | Many decades of trials behind registered oral cannabinoids overseas | The comparison route most studies measure against |
| Plain THC in a suppository base | ElSohly and colleagues found no THC bioavailability from suppository formulations of THC itself in monkeys (1991) | None that shows useful absorption | Not a route the studies support |
| THC-hemisuccinate prodrug suppository | About 2.4 times the oral THC exposure in 12 healthy men (ElSohly 2018); 13.5 percent in monkeys | Three small human studies: 3 women, 2 patients, and 42 healthy men in total | No commercial product; the authors state it is no longer under any commercialisation agreement |
| Modern extract suppository | Bioavailability somewhat lower than oromucosal comparators in 12 healthy volunteers (Tarlovski 2025) | One single-dose study by the manufacturer | Unregistered in South Africa as far as we could establish |
| Vaginal suppository | No human pharmacokinetic study found in a PubMed search run for this page | One preference survey and one small preliminary trial | Unregistered; any THC product would be Schedule 6 |
Before you start
In South Africa, medical cannabis containing THC is a Schedule 6 prescription medicine, available through a registered doctor and, where the product is not registered here, a SAHPRA section 21 authorisation. This page is general information for adults aged 18 and over and is not medical advice. It deliberately contains no dosing, insertion or timing instructions, because those depend on the product, your condition and your other medicines. Speak to your doctor or pharmacist about dosing and use, and tell them about every other medicine you take.
What about vaginal cannabis suppositories?
There is clear patient interest but almost no pharmacology behind the vaginal route. A PubMed search run for this page on 18 September 2026 for vaginal THC or CBD pharmacokinetics returned no human study, so nobody can say from published data how much reaches the bloodstream or the pelvic tissues.
The interest is documented. In a 2023 cross-sectional study at two Canadian tertiary pelvic pain centres, Yang and colleagues surveyed women with myofascial pelvic pain: 77 of 135 respondents used cannabis, and approximately three in four respondents said they would be willing to try vaginal or vulvar cannabis products. The authors concluded that such products warrant further research, not that they work.
The only trial-style data we found is a 2024 preliminary study by Banbury and colleagues in 83 women after gynaecological cancer treatment. Participants were recruited through TikTok and LinkedIn and allocated according to whether they already used cannabis suppositories, so the cannabis element was not randomised. Sexual pain was reduced in the cannabis groups, and the authors call the results preliminary and exploratory.
Why is the evidence for medical cannabis suppositories so thin?
Because the route has barely been studied and the product that showed promise never reached the market. Franjo Grotenhermen’s 2003 review of cannabinoid pharmacokinetics described the rectal route as used in only a few studies and of little relevance in practice, and the human data added since then fits on one page.
The strongest evidence summaries do not cover it at all. The 2017 National Academies of Sciences, Engineering and Medicine report found conclusive or substantial evidence for cannabis in chronic pain in adults, and for oral cannabinoids in chemotherapy-induced nausea and vomiting and patient-reported multiple sclerosis spasticity. None of those conclusions rests on suppositories.
Then there is supply. The 2018 paper notes that the product evaluated is no longer under any intellectual property or commercialisation agreement, so the formulation with the best human data cannot be ordered, and products sold online as cannabis suppositories are a different, untested formulation.
If swallowing is difficult or oral cannabis has not suited you, that is a clinical conversation about alternatives, not a reason to buy an untested product. Register for Professor Green store access to start with an assessment by a registered doctor, who can compare routes with you. Registration does not guarantee eligibility, a prescription or supply.
Can you get medical cannabis suppositories legally in South Africa?
Only as a prescription medicine, and in practice only as an unregistered product. THC is listed in Schedule 6 under Government Notice 586 (Government Gazette 43347, 22 May 2020), so a THC suppository needs a registered doctor, a SAHPRA section 21 authorisation where it is not registered, and dispensing by a pharmacy.
Section 14 of the Medicines and Related Substances Act 101 of 1965 prohibits the sale of a medicine subject to registration unless it is registered, subject to exceptions including section 21, under which SAHPRA may authorise the sale of a specified quantity of an unregistered medicine to a specified person or institution for a specified period. We are not aware of a cannabis suppository registered with SAHPRA and could not verify the register from our side, so plan on the section 21 route unless your pharmacist tells you otherwise. Our step-by-step guide to a section 21 application explains why the doctor, not the patient, is the applicant.
Compounding is also regulated. The Act allows a pharmacist to compound a medicine for a particular patient in the quantity needed for treatment, and section 22C(5) says no person may compound or dispense a medicine unless authorised under the Pharmacy Act, a veterinarian, or licensed to do so. A suppository mixed at home or by an unlicensed seller does not fit either description. How a registered pharmacy dispenses medical cannabis is covered separately.
CBD does not escape this. Under the same notice CBD is Schedule 4, with Schedule 0 exceptions limited to low-risk complementary medicines and certain ingested products, so a CBD suppository promoted for pain or pelvic conditions falls outside them.
The Cannabis for Private Purposes Act 7 of 2024 does not change this: it comes into operation only on a date fixed by presidential proclamation, and it concerns private adult use, not medicines.
What should you ask your doctor before trying this route?
Ask what the product actually contains. The published absorption advantage belongs to THC-hemisuccinate, so a product made from ordinary extract should not be assumed to behave the same way. Our page on medical cannabis capsules and the oral route is the natural comparison, because that is the route most prescribers know best.
Ask about effects on the whole body. The 2018 study measured THC and its active metabolite in the bloodstream after rectal dosing, so a suppository is not a way to avoid impairment, and the same cautions about driving and machinery apply. Ask too about interactions, because THC and CBD share liver enzymes with many common medicines; our guide to cannabis drug interactions lists what to check.
Finally, ask who you should tell if something goes wrong. Local irritation, unexpected intoxication or any other suspected reaction belongs with your prescriber and pharmacist first, and SAHPRA runs an adverse drug reaction and quality problem reporting process for exactly these reports.
How Professor Green fits into the process
Professor Green is a South African medical cannabis access platform and a marketing affiliate of the Dr Green network, which holds the medical cannabis licences in South Africa. Professor Green does not itself sell, handle or ship cannabis. Products are sold and fulfilled by the licensed operator.
Every regulated decision sits with someone else. A registered doctor assesses you and decides whether any cannabis medicine, in any form, is appropriate, and applies to SAHPRA under section 21 where the product is unregistered. A registered pharmacy dispenses, and the licensed operator supplies. Professor Green performs none of those acts and does not advise on dosing.
That division matters here. Whether medical cannabis suppositories are worth considering for you is a prescribing judgement, and questions or side-effect reports about a prescribed product go to the doctor and pharmacist who handled it.
Frequently asked questions
Do medical cannabis suppositories get you high?
They can if they contain THC. The 2018 study by ElSohly and colleagues measured THC and its metabolites in the bloodstream after rectal dosing, so effects on the whole body are expected. Peak levels were lower and later than after an oral capsule, but that is not the same as no impairment.
Are suppositories absorbed better than capsules?
Only one specific form has shown that. A THC-hemisuccinate suppository gave about 2.4 times the THC exposure of an oral capsule in 12 healthy men in 2018, while plain THC in a suppository base showed no bioavailability in 1991 animal studies.
Is there a registered cannabis suppository in South Africa?
We are not aware of one, and we could not check the SAHPRA register from our side. Treat any prescribed THC suppository as an unregistered product that needs a section 21 authorisation, and ask your pharmacist to confirm its status.
Is there evidence for vaginal cannabis suppositories?
Very little. A 2023 survey found about three in four women with pelvic pain would be willing to try vaginal or vulvar cannabis products, and a small 2024 preliminary study reported reduced sexual pain without randomising cannabis use. We found no human absorption study.
Can I make my own cannabis suppositories?
No, and this page gives no instructions for doing so. THC is Schedule 6, compounding is restricted to pharmacists and licensed persons, and ordinary THC in a suppository base is poorly absorbed anyway.
Are CBD suppositories sold online legal?
Usually not as sold. CBD is Schedule 4 in South Africa, with narrow Schedule 0 exceptions for complementary medicines making only a low-risk claim within set limits and for certain ingested products. A CBD suppository promoted for pain or pelvic conditions is making a therapeutic claim outside those exceptions.
What dose or insertion method should I use?
That is for your prescriber and pharmacist, who know the product, your condition and your other medicines. This page deliberately gives no dosing, timing or insertion guidance.
Sources and references
- ElSohly MA, Gul W, Walker LA, Pharmacokinetics and Tolerability of THC-Hemisuccinate in a Suppository Formulation as an Alternative to Capsules for the Systemic Delivery of THC, Medical Cannabis and Cannabinoids 2018
- Mattes RD et al, Bypassing the first-pass effect for the therapeutic use of cannabinoids, Pharmacology Biochemistry and Behavior 1993
- Brenneisen R et al, The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients, Int J Clin Pharmacol Ther 1996
- ElSohly MA et al, Rectal bioavailability of delta-9-tetrahydrocannabinol from the hemisuccinate ester in monkeys, J Pharm Sci 1991
- ElSohly MA et al, Rectal bioavailability of delta-9-tetrahydrocannabinol from various esters, Pharmacol Biochem Behav 1991
- Tarlovski S et al, Comparative Pharmacokinetic Assessment of Innovative Sublingual, Rectal and Vaporizer Cannabis Products Versus Approved Cannabis Products in Healthy Volunteers, Cannabis Cannabinoid Res 2025
- Huestis MA, Human Cannabinoid Pharmacokinetics, Chemistry and Biodiversity 2007
- Grotenhermen F, Pharmacokinetics and pharmacodynamics of cannabinoids, Clinical Pharmacokinetics 2003
- Yang EC et al, Cannabis use preferences in women with myofascial pelvic pain: A cross-sectional study, Eur J Obstet Gynecol Reprod Biol X 2023
- Banbury S et al, A Preliminary Investigation into the Use of Cannabis Suppositories and Online Mindful Compassion for Improving Sexual Function Among Women Following Gynaecological Cancer Treatment, Medicina 2024
- National Academies of Sciences, Engineering and Medicine, The Health Effects of Cannabis and Cannabinoids (2017), report conclusions
- SAHPRA, Communication to Industry on the scheduling status of THC and CBD (GN 586, GG 43347, 22 May 2020)
- SAHPRA, Section 21 access to unregistered medicines
- Medicines and Related Substances Act 101 of 1965 (sections 14, 21 and 22C)
- SAHPRA, adverse drug reaction and quality problem reporting form
Research figures on this page are taken from the studies cited above, most of which are very small, and are stated as at 18 September 2026. The legal position described is South African law as at the same date; statutory provisions are paraphrased, so consult the published text for exact wording. This page is general information for adults aged 18 and over. It is not medical advice, contains no dosing, timing or insertion guidance, and does not replace a consultation with a registered doctor or pharmacist.
Talk to a doctor before choosing a route
The research on medical cannabis suppositories is small, and the best-studied formulation is not on the market. If you want to know whether any cannabis medicine suits you, and in what form, the next step is an assessment by a registered doctor. Professor Green connects you to that route: the doctor assesses and prescribes, a pharmacy dispenses, and a licensed operator supplies. Registration does not guarantee eligibility or supply.
Register for Store Access

